These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 9576283)

  • 21. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
    Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
    J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2001 Nov; 16(11):1290-6. PubMed ID: 11903749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
    Lok AS; Sterling RK; Everhart JE; Wright EC; Hoefs JC; Di Bisceglie AM; Morgan TR; Kim HY; Lee WM; Bonkovsky HL; Dienstag JL;
    Gastroenterology; 2010 Feb; 138(2):493-502. PubMed ID: 19852963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Role of Blood Tumor Markers in Predicting Hepatocellular Carcinoma in Liver Cirrhosis Patients Undergoing Liver Transplantation.
    Kim Y; Park YH; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Park GC; Lee SG
    Ann Transplant; 2016 Oct; 21():660-667. PubMed ID: 27777395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
    Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
    Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves.
    Fujiyama S; Izuno K; Yamasaki K; Sato T; Taketa K
    Tumour Biol; 1992; 13(5-6):316-23. PubMed ID: 1283927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
    Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
    Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
    Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
    Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
    Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W;
    Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
    Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
    Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.
    Grazi GL; Mazziotti A; Legnani C; Jovine E; Miniero R; Gallucci A; Palareti G; Gozzetti G
    Liver Transpl Surg; 1995 Jul; 1(4):249-55. PubMed ID: 9346575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum Des-gamma-carboxy Prothrombin for Diagnosis of Adult Primary Cancer in Liver.
    Li Y; Chen J
    J Coll Physicians Surg Pak; 2019 Oct; 29(10):972-976. PubMed ID: 31564273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
    Hamamura K; Shiratori Y; Shiina S; Imamura M; Obi S; Sato S; Yoshida H; Omata M
    Cancer; 2000 Apr; 88(7):1557-64. PubMed ID: 10738213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
    Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
    Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin.
    Kurokawa T; Yamazaki S; Mitsuka Y; Moriguchi M; Sugitani M; Takayama T
    Br J Cancer; 2016 Jan; 114(1):53-8. PubMed ID: 26679378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma.
    Tameda M; Shiraki K; Sugimoto K; Ogura S; Inagaki Y; Yamamoto N; Ikejiri M; Takei Y; Ito M; Nobori T
    Cancer Sci; 2013 Jun; 104(6):725-31. PubMed ID: 23480217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.